

IIQ COMPLETES PLACEMENT AND LODGES SPP OFFER BOOKLET

INOVIQ Limited (ASX: IIQ) (**INOVIQ** or the **Company**) is pleased to announce that it has successfully completed the issue of 27,142,856 fully paid ordinary shares to institutional and sophisticated investors today (**Placement**), as previously announced to the ASX on Monday, 13 October 2025.

As also announced on Monday, 13 October 2025, INOVIQ today launched a Share Purchase Plan Offer (**Offer**) which contains an offer of new fully paid ordinary shares in the Company (**Shares**) under a share purchase plan (**SPP**) to existing shareholders with a registered address in Australia or New Zealand as at 7.00pm (Sydney time) on 10 October 2025 (**Eligible Shareholders**). The SPP provides each Eligible Shareholder with an opportunity to apply for up to \$30,000 worth of new Shares at an issue price of \$0.35 per Share, being the same price as under the Placement. The Company is seeking to raise up to \$2 million through the SPP with the capacity to accept oversubscriptions at the Company's complete discretion. INOVIQ reserves the right to scale back oversubscriptions under the SPP in its absolute discretion.

The SPP Booklet will be dispatched to Eligible Shareholders today, Friday, 17 October 2025.

The SPP is scheduled to open today and close at 5pm (Sydney time) on Wednesday, 29 October 2025.

IIQ expects the Shares issued under the SPP to commence trading on a normal settlement basis on or about Wednesday, 5 November 2025.

Authorised for release by Company Secretary, Mark Edwards.

FURTHER INFORMATION

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

David Williams
Chairman
E dwilliams@kidder.com.au
M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics to transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit www.inoviq.com.